Endo wins dismissal of FTC lawsuit over Impax opioid deal

By Khorri Atkinson (March 24, 2022, 3:40 p.m. EDT) — Endo Pharmaceuticals on Thursday won a DC federal court dismissal of the Federal Trade Commission’s antitrust lawsuit accusing it of entering into a second “payment for delay” with Impax Laboratories to avoid competition from Endo’s Opana ER painkiller.

U.S. District Judge Royce C. Lamberth, in a sealed order, agreed to dismiss the case against the two drugmakers alongside Impax owner Amneal Pharmaceuticals Inc. due to the “failure to report” of the FTC.

In a separate one-page order in the case file, Judge Lamberth explained that his opinion was sealed because it referred to documents that the district court allowed the parties to file as…

Stay one step ahead

In the legal profession, information is the key to success. You need to know what’s going on with customers, competitors, practice areas and industries. Law360 provides the intelligence you need to stay an expert and beat the competition.

  • Access to case data in articles (numbers, filings, courts, nature of lawsuits, etc.)
  • Access to attached documents such as briefs, motions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and more!



Comments are closed.